- Our Story
- Our Products
- Our Science
- Our People
- Our Citizenship
-
Investors
- Reports and Filings
- Presentations
-
Shares
- Share Price
- Stock Updates
- Equity & Dividend History
- Unpaid & Unclaimed Dividend
- Analyst Coverage
- Shareholding Pattern
- Share Transfer Information
- Buyback
- Details of Shares for transfer to IEPF August 17
- Notice pursuant to IEPF Rules, Aug 17
- Details of Shares for transfer to IEPF May 2018
- Notice pursuant to IEPF Rules, May 2018
- Details of Shares for transfer to IEPF May 2019
- Notice Pursuant to IEPF Rules, May 2019
- Governance
- Investor Services
- Media
- Partners
- Canada
- Australia
- Germany
- India
- New Zealand
- China
- Netherlands
- Spain
- Contact Us
Press Releases
Aug
Jul
- Dr. Reddy's Laboratories announces the launch of Pregabalin Capsules in the U.S. Market
- Dr. Reddy’s Q1 FY20 Financial Results
- Dr. Reddy's Laboratories announces the launch of Ramelteon Tablets, in the U.S. Market
- Dr. Reddy’s Laboratories announces closure of the transaction to divest ZEMBRACE® SYMTOUCH® and TOSYMRATM to Upsher-Smith Laboratories, LLC
- Dr. Reddy’s announces the launch of over-the-counter, store-brand equivalent of Allegra-D® 12 HR Allergy and Congestion Extended-Release Tablets (fexofenadine HCl 60 mg and pseudoephedrine HCl 120 mg) in the U.S. Market
- Dr. Reddy’s announces the launch of the over-the-counter store brand equivalent of Mucinex® D Extended Release Tablets in two strengths in the U.S. Market
- Dr. Reddy's Laboratories announces first-to-market launch of Carboprost Tromethamine Injection USP, 250 mcg/mL (1mL) Single-dose Vial in the U.S. Market
Jun
- Dr. Reddy's Laboratories announces the launch of Tobramycin Inhalation Solution, USP in the U.S. Market
- Dr. Reddy's Laboratories announces the launch of Phytonadione Injectable Emulsion USP, 10 mg/ml Single-Dose Ampules in the U.S. Market
- Dr. Reddy’s Laboratories announces entering into a definitive agreement to sell its neurology branded products to Upsher-Smith Laboratories, LLC
- Dr. Reddy's Laboratories Limited to present at the Goldman Sachs 40th Annual Global Healthcare Conference
- Dr. Reddy's Laboratories Limited through its wholly owned subsidiary, Dr. Reddy’s Laboratories SA, announces positive topline results from Phase 2b study of PPC-06 in patients with moderate to severe plaque psoriasis
- Dr. Reddy's Laboratories announces the re-launch of Zenatane® (Isotretinoin Capsules, USP), 10 mg, 20 mg, 30 mg and 40 mg in the U.S. Market
- Dr. Reddy's Laboratories announces filing of Annual Report on Form 20-F
May
Apr
Mar
Feb
Jan
- Dr. Reddy's Laboratories and its U.S. subsidiary, Promius Pharma, announce FDA approval for TOSYMRA™ (sumatriptan nasal spray) 10 mg, in the U.S. market
- Dr. Reddy's Laboratories announces the launch of Propofol Injectable Emulsion, USP in the U.S. Market
- Dr. Reddy's Laboratories Limited to present at the 37th Annual J.P. Morgan Healthcare Conference
